Avalo Therapeutics (AVTX) Non-Current Assets (2014 - 2026)

Avalo Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $11.1 million for Q1 2026.

• Quarterly Non-Current Assets fell 4.51% year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.9 million (down 6.77% YoY) and the FY2025 annual result came in at $11.2 million, down 5.66% from the prior year.
• Non-Current Assets was $11.1 million for Q1 2026 at Avalo Therapeutics, down from $11.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $18.2 million in Q1 2022 and bottomed at $11.1 million in Q1 2026.
• A 5-year average of $14.0 million and a median of $12.5 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets gained 5.75% — and 2024, when it declined 26.3%.
• Avalo Therapeutics' Non-Current Assets stood at $17.0 million in 2022, then dropped by 25.68% to $12.6 million in 2023, then decreased by 6.0% to $11.8 million in 2024, then declined by 5.66% to $11.2 million in 2025, then retreated by 1.0% to $11.1 million in 2026.
• Business Quant data shows AVTX's Non-Current Assets at $11.1 million in Q1 2026, $11.2 million in Q4 2025, and $11.3 million in Q3 2025.